# A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

> **NCT04560244** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 15 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** SHR1701

## Key facts

- **NCT ID:** NCT04560244
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2022-09
- **Final completion:** 2022-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560244, "A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04560244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*